The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete.

The reader should not assume that the information is accurate and complete.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549 **FORM D**

Notice of Exempt Offering of Securities

OMB APPROVAL

OMB Number: 3235-0076 Estimated average burden hours per response: 4.00

1. Issuer's Identity			
1. Issuer's identity			
CIK (Filer ID Number)	Previous Names	X None	Entity Type
0001878313			X Corporation
Name of Issuer			Limited Partnership
MAIA Biotechnology, Inc.			
Jurisdiction of Incorporation/Organ	ization		Limited Liability Company
DELAWARE			General Partnership
Year of Incorporation/Organization			Business Trust
X Over Five Years Ago			Other (Specify)
Within Last Five Years (Specify	Year)		
H	reary		
Yet to Be Formed			
2. Principal Place of Business an	d Contact Information		
Name of Issuer			
MAIA Biotechnology, Inc.			
Street Address 1		Street Address 2	
444 WEST LAKE STREET		SUITE 1700	
City	State/Province/Country	ZIP/PostalCode	Phone Number of Issuer
CHICAGO	ILLINOIS	60606	312-416-8592
3. Related Persons			
Last Name	First Name		Middle Name
Vitoc	Vlad		
Street Address 1	Street Address 2		
444 West Lake Street	Suite 1700		
City	State/Province/Cou	ntry	ZIP/PostalCode
Chicago	ILLINOIS		60606
Relationship: X Executive Officer	X Director Promoter		
Clarification of Response (if Neces	sary):		
Chief Executive Officer, President and	Chairman of the Board of Directors		
Last Name	First Name		Middle Name
Himmelreich	Jeffrey		made rume
Street Address 1	Street Address 2		
444 West Lake Street	Suite 1700		
City	State/Province/Cou	ntrv	ZIP/PostalCode
Chicago	ILLINOIS	,	60606
Relationship: X Executive Officer	Director Promoter		
Clarification of Response (if Neces			
Head of Finance	эм у _/ .		
Last Name	First Name		Middle Name
Gryaznov	Sergei		
Street Address 1	Street Address 2		
444 West Lake Street	Suite 1700		
City	State/Province/Cou	ntry	ZIP/PostalCode
Chicago	ILLINOIS	•	60606

Relationship: X Executive Officer Director	Promoter		
Clarification of Response (if Necessary):			
Chief Scientific Officer			
Last Name	First Name	Middle Name	
Theagene	Jean-Manasse		
Street Address 1	Street Address 2		
444 West Lake Street	Suite 1700		
City	State/Province/Country	ZIP/PostalCode	
Chicago	ILLINOIS	60606	
Relationship: Executive Officer X Director	Promoter		
Clarification of Response (if Necessary):	_		
Last Name	First Name	Middle Name	
Chaouki	Steven	Wilder Name	
Street Address 1	Street Address 2		
444 West Lake Street	Suite 1700		
		ZID/DootolCodo	
City	State/Province/Country ILLINOIS	ZIP/PostalCode	
Chicago	_	60606	
Relationship: Executive Officer X Director	Promoter		
Clarification of Response (if Necessary):			
Last Name	First Name	Middle Name	
Smith	Stan		
Street Address 1	Street Address 2		
444 West Lake Street	Suite 1700		
City	State/Province/Country	ZIP/PostalCode	
Chicago	ILLINOIS	60606	
	-		
Relationship: Executive Officer Director Clarification of Response (if Necessary):	Promoter		
Ciamication of Response (if Necessary).			
Last Name	First Name	Middle Name	
Guerrero	Ramiro		
Street Address 1	Street Address 2		
444 West Lake Street	Suite 1700		
City	State/Province/Country	ZIP/PostalCode	
Chicago	ILLINOIS	60606	
Relationship: Executive Officer X Director	Promoter		
Clarification of Response (if Necessary):	_		
Lost Name	First Name	Maddla Norre	
Last Name	First Name	Middle Name	
Yee	Louie	Ngar	
Street Address 1	Street Address 2		
444 West Lake Street	Suite 1700		
City	State/Province/Country	ZIP/PostalCode	
Chicago	ILLINOIS	60606	
Relationship: Executive Officer X Director	Promoter		
Clarification of Response (if Necessary):			
Last Name	First Name	Middle Name	
Luput	Cristian		
Street Address 1	Street Address 2		
444 West Lake Street	Suite 1700		
City	State/Province/Country	ZIP/PostalCode	
Chicago	ILLINOIS	60606	
Relationship: Executive Officer X Director	_		
Clarification of Response (if Necessary):			

4. Industry Group			
П	Health Care		
Agriculture Banking & Financial Services	Retailing X Biotechnology		
Commercial Banking	Restaurants		
Insurance	Health Insurance Technology		
Investing	Hospitals & Physicians Computers		
Investment Banking	Pharmaceuticals Telecommunications		
Pooled Investment Fund	Other Health Care Other Technology		
Is the issuer registered as	Manufacturing Travel		
an investment company under	Real Estate Airports		
the Investment Company Act of 1940?	Commercial		
Yes No	Lodging & Conventions		
Other Banking & Financial Services	Construction Tourism & Travel Services		
Business Services	REITS & Finance Other Travel		
Energy	Residential Other		
Coal Mining	Other Real Estate		
☐ Electric Utilities			
Energy Conservation			
Environmental Services			
Oil & Gas			
Other Energy			
5. Issuer Size			
Revenue Range OR	Aggregate Net Asset Value Range		
No Revenues	No Aggregate Net Asset Value		
\$1 - \$1,000,000	\$1 - \$5,000,000		
\$1,000,001 - \$5,000,000	\$5,000,001 - \$25,000,000		
\$5,000,001 - \$25,000,000	\$25,000,001 - \$50,000,000		
\$25,000,001 - \$100,000,000	\$50,000,001 - \$100,000,000		
Over \$100,000,000	Over \$100,000,000		
X Decline to Disclose	Decline to Disclose		
Not Applicable	Not Applicable		
6. Federal Exemption(s) and Exclusion(s)	Claimed (select all that apply)		
er roudial Exemplication (e)	Statistical (Solott all trial apply)		
	Investment Company Act Section 3(c)		
Rule 504(b)(1) (not (i), (ii) or (iii))	Section 3(c)(1) Section 3(c)(9)		
Rule 504 (b)(1)(i)			
Rule 504 (b)(1)(ii)	Section 3(c)(2) Section 3(c)(10)		
Rule 504 (b)(1)(iii)	Section 3(c)(3) Section 3(c)(11)		
X Rule 506(b)	Section 3(c)(4) Section 3(c)(12)		
Rule 506(c)	Section 3(c)(5) Section 3(c)(13)		
Securities Act Section 4(a)(5)	Section 3(c)(6) Section 3(c)(14)		
	Section 3(c)(7)		
7. Type of Filing			
X New Notice Date of First Sale 2025-05-2	First Sale Yet to Occur		
Amendment			
8. Duration of Offering			
Done the leguer intend this effection to look	nore than one year? $\sqrt{\text{Yes} X}$ No		
Does the Issuer intend this offering to last n	iore than one year? Tes Ano		

9. Type(s) of Securities Offered (select all that apply)				
We	По ти то то то т			
X Equity	H	Pooled Investment Fund Interests		
Debt	☐ Tenant-in-Common Securities			
Option, Warrant or Other Right to Acquire Another Security	Mineral Property Securities			
Security to be Acquired Upon Exercise of Option, Warrant or Other Rig Acquire Security	ght to Other (describe)			
10. Business Combination Transaction				
Is this offering being made in connection with a business combination tra exchange offer?	insaction, such as a merger, acquisition or $\ \ \ \ \ \ \ \ \ \ \ \ \ $			
Clarification of Response (if Necessary):				
11. Minimum Investment				
Minimum investment accepted from any outside investor $\$0$ USD				
12. Sales Compensation				
Recipient	Recipient CRD Number X None			
None	None			
(Associated) Broker or Dealer X None	(Associated) Broker or Dealer CRD Number X None			
—				
None Street Address 1	None Street Address 2			
None	None			
City	State/Province/Country	ZIP/Postal Code		
None	Unknown	None		
State(s) of Solicitation (select all that apply) Check "All States" or check individual States $\overline{\mathbf{X}}$ All States	Foreign/non-US			
13. Offering and Sales Amounts				
Total Offering Amount \$8,000,000 USD or Indefinite				
Total Amount Sold \$694,998 USD				
Total Remaining to be Sold \$7,305,002 USD or Indefinite				
Clarification of Response (if Necessary):				
14. Investors				
Select if securities in the offering have been or may be sold to person such non-accredited investors who already have invested in the offering Regardless of whether securities in the offering have been or may be total number of investors who already have invested in the offering:	ing.			
15. Sales Commissions & Finder's Fees Expenses				
Provide separately the amounts of sales commissions and finders fees excheck the box next to the amount.	xpenses, if any. If the amount of an expenditure is not known, provide	e an estimate and		
Sales Commissions \$0 USD Estimate				
Finders' Fees \$0 USD Estimate				
Clarification of Response (if Necessary):				
16. Use of Proceeds				
Provide the amount of the gross proceeds of the offering that has been or executive officers, directors or promoters in response to Item 3 above. If t				
\$0 USD ☐ Estimate				
Clarification of Response (if Necessary):				
Signature and Submission				
Please verify the information you have entered and review the Terms	s of Submission below before signing and clicking SUBMIT belo	ow to file this notice.		

Terms of Submission

In submitting this notice, each issuer named above is:

- Notifying the SEC and/or each State in which this notice is filed of the offering of securities described and undertaking to furnish them, upon written request, in the accordance with applicable law, the information furnished to offerees.*
- Irrevocably appointing each of the Secretary of the SEC and, the Securities Administrator or other legally designated officer of the State in which the issuer maintains its principal place of business and any State in which this notice is filed, as its agents for service of process, and agreeing that these persons may accept service on its behalf, of any notice, process or pleading, and further agreeing that such service may be made by registered or certified mail, in any Federal or state action, administrative proceeding, or arbitration brought against the issuer in any place subject to the jurisdiction of the United States, if the action, proceeding or arbitration (a) arises out of any activity in connection with the offering of securities that is the subject of this notice, and (b) is founded, directly or indirectly, upon the provisions of: (i) the Securities Act of 1933, the Securities Exchange Act of 1934, the Trust Indenture Act of 1939, the Investment Company Act of 1940, or the Investment Advisers Act of 1940, or any rule or regulation under any of these statutes, or (ii) the laws of the State in which the issuer maintains its principal place of business or any State in which this notice is filed.
- Certifying that, if the issuer is claiming a Regulation D exemption for the offering, the issuer is not disqualified from relying on Rule 504 or Rule 506 for one of the reasons stated in Rule 504(b)(3) or Rule 506(d).

Each Issuer identified above has read this notice, knows the contents to be true, and has duly caused this notice to be signed on its behalf by the undersigned duly authorized person.

For signature, type in the signer's name or other letters or characters adopted or authorized as the signer's signature.

Issuer	Signature	Name of Signer	Title	Date
MAIA Biotechnology, Inc.	/s/ Vlad Vitoc	Vlad Vitoc	Chief Executive Officer	2025-06-11

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

* This undertaking does not affect any limits Section 102(a) of the National Securities Markets Improvement Act of 1996 ("NSMIA") [Pub. L. No. 104-290, 110 Stat. 3416 (Oct. 11, 1996)] imposes on the ability of States to require information. As a result, if the securities that are the subject of this Form D are "covered securities" for purposes of NSMIA, whether in all instances or due to the nature of the offering that is the subject of this Form D, States cannor routinely require offering materials under this undertaking or otherwise and can require offering materials only to the extent NSMIA permits them to do so under NSMIA's preservation of their anti-fraud authority.